Vivace Therapeutics Raises $35 Million In Series D Financing To Support Clinical Development Of First-In-Class Cancer Drug Targeting The Hippo Pathway
Summary
* VIVACE THERAPEUTICS RAISES $35 MILLION IN SERIES D FINANCING TO SUPPORT CLINICAL DEVELOPMENT OF FIRST-IN-CLASS CANCER DRUG TARGETING THE HIPPO PATHWAY Source text:
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected